6-氯-2-哌嗪-1,3-苯并噻唑 | 153025-29-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 6-氯-2-哌嗪-1,3-苯并噻唑
• 英文名称: 6-chloro-2-piperazin-1-yl-benzothiazole
• 英文别名: 6-chloro-2-(piperazin-1-yl)benzothiazole；6-chloro-2-piperazin-1-ylbenzothiazole；1-(6-chloro-2-benzothiazolyl)piperazine；1-(6-chlorobenzothiazol-2-yl)piperazine；N-(6-chlorobenzothiazol-2-yl)piperazine；6-chloro-2-(1-piperazinyl)benzothiazole；6-Chloro-2-piperazino-1,3-benzothiazole；6-chloro-2-piperazin-1-yl-1,3-benzothiazole
• CAS: 153025-29-7
• 化学式: C₁₁H₁₂ClN₃S
• 分子量: 253.755
• InChiKey: HKQTVOYPBKNRJL-UHFFFAOYSA-N

物化性质

• 沸点：
  402.1±55.0 °C(Predicted)
• 密度：
  1.360±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  56.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934200090

反应信息

• 作为反应物：
  描述：

  6-氯-2-哌嗪-1,3-苯并噻唑 、 alpha-氯乙酰苯 在 sodium carbonate 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以81%的产率得到2-(4-(6-chlorobenzo[d]thiazol-2-yl)piperazin-1-yl)-1-phenylethanone
  参考文献：
  名称：

  Design, Synthesis and Biological Activity Evaluation of Arylpiperazine Derivatives for the Treatment of Neuropathic Pain

  摘要：

  在这项工作中，一系列苯基哌嗪衍生物被合成并通过体内药理学试验进行筛选。在测试的化合物中，2-(4-(3-(三氟甲基)苯基)哌嗪-1-基)-1-苯乙酮（18）和2-(4-(2,3-二甲基苯基)哌嗪-1-基)-1-苯乙酮（19）在小鼠扭体和大鼠热板实验中表现出强大的镇痛活性。在扭体实验中，它们相对于对照组显示出超过70%的抑制率，且在热板测试中分别将延迟时间增加了116.0%和134.4%。此外，化合物18在没有镇静副作用的情况下，在福尔马林痛和神经病理性痛模型中也表现出活性。

  DOI：

  10.3390/molecules16075785
• 作为产物：
  描述：

  tert-butyl 4-(6-chlorobenzothiazol-2-yl)piperazine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以710 mg的产率得到6-氯-2-哌嗪-1,3-苯并噻唑
  参考文献：
  名称：

  Small molecules enhance functional O-mannosylation of Alpha-dystroglycan

  摘要：

  Alpha-dystroglycan (alpha-DG), a highly glycosylated receptor for extracellular matrix proteins, plays a critical role in many biological processes. Hypoglycosylation of alpha-DG results in various types of muscular dystrophies and is also highly associated with progression of majority of cancers. Currently, there are no effective treatments for those devastating diseases. Enhancing functional O-mannosyl glycans (FOG) of alpha-DG on the cell surfaces is a potential approach to address this unmet challenge. Based on the hypothesis that the cells can up-regulate FOG of alpha-DG in response to certain chemical stimuli, we developed a cell-based high-throughput screening (HTS) platform for searching chemical enhancers of FOG of alpha-DG from a large chemical library with 364,168 compounds. Sequential validation of the hits from a primary screening campaign and chemical works led to identification of a cluster of compounds that positively modulate FOG of alpha-DG on various cell surfaces including patient-derived myoblasts. These compounds enhance FOG of alpha-DG by almost ten folds, which provide us powerful tools for O-mannosylation studies and potential starting points for the development of drug to treat dystroglycanopathy. (c) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.11.011

文献信息

• REMEDIES OR PREVENTIVES FOR AIDS
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0878194A1

  公开（公告）日：1998-11-18

  The present invention is to provide the combined use of one kind or two or more kinds of a quinolone carboxylic acid having anti-HIV activity and one kind or two or more kinds of a reverse transcriptase inhibitor or HIV protease inhibitor, and an AIDS therapeutic agent or preventive agent containing as its active ingredients one kind or two or more kinds of a quinolone carboxylic acid having anti-HIV activity and one kind or two or more kinds of a reverse transcriptase inhibitor or HIV protease inhibitor.

  本发明提供了一种或两种或两种以上具有抗HIV活性的喹诺酮羧酸与一种或两种或两种以上的逆转录酶抑制剂或HIV蛋白酶抑制剂的联合使用，以及一种包含作为其活性成分的抗HIV活性的喹诺酮羧酸和一种或两种或两种以上的逆转录酶抑制剂或HIV蛋白酶抑制剂的艾滋病治疗剂或预防剂。
• Sulfonamide derivatives as 5-HT7 receptor antagonists
  申请人：SmithKline Beecham p.l.c.

  公开号：US06660751B1

  公开（公告）日：2003-12-09

  The invention relates to novel sulfonamide compounds having 5-HT7 receptor antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders. wherein: Q is phenyl or thienyl; R1 is halogen, hydroxy, C1-6alkyl, CF3, OCF3 or C1-6alkoxy; m is 0, 1, 2 or 3; R2 is C1-4alkyl; X is carbon or CH, is a single bond when X is nitrogen or CH or is a double bond when X is carbon, D is a single bond, C═O, O or CH2 subject to the proviso that when X is nitrogen then D is not oxygen; P is a 5 or 6 membered heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a benzofused heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur; R3 is C1-6alkyl optionally substituted by NR4R5, aryl, arylC1-6alkyl, C1 6alkoxy, C1-6alkylthio, cyano, hydroxy, nitro, halogen, CF3, C2F5, NR4R5, CONR4R5, NR4COR5, S(O)pNR4R5, CHO, OCF3, SCF3, CH2OR6, CO2R6 or COR6 where p is 0, 1 or 2 and R4, R5 and R6 are independently hydrogen, C1-6alkyl, aryl or arylC1-6alkyl; n is 0, 1, 2 or 3.

  该发明涉及具有5-HT7受体拮抗活性的新型磺胺类化合物，其制备方法，含有它们的组合物以及它们在治疗中枢神经系统和其他疾病中的用途。 其中： Q为苯基或噻吩基； R1为卤素、羟基、C1-6烷基、三氟甲基、OCF3或C1-6烷氧基； m为0、1、2或3； R2为C1-4烷基； X为碳或CH， 当X为氮或CH时，为单键， 当X为碳时，为双键， D为单键、C═O、O或CH2，但当X为氮时，D不是氧； P为含有1至3个氧、氮和硫杂原子的5或6元杂芳基环，或者含有1至3个氧、氮和硫杂原子的苯并杂芳基环； R3为C1-6烷基，可选择地被NR4R5、芳基、芳基C1-6烷基、C1-6烷氧基、C1-6烷基硫基、氰基、羟基、硝基、卤素、三氟甲基、C2F5、NR4R5、CONR4R5、NR4COR5、S(O)pNR4R5、CHO、OCF3、SCF3、 OR6、CO2R6或COR6取代，其中p为0、1或2，R4、R5和R6独立地为氢、C1-6烷基、芳基或芳基C1-6烷基； n为0、1、2或3。
• Condensed thiophene compound and pharmaceutical use thereof
  申请人：Yoshitomi Pharmaceutical Industries, Ltd.

  公开号：US05532240A1

  公开（公告）日：1996-07-02

  A condensed thiophene compound represented by general formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein ring S represents a thiophene ring; R.sup.1 represents hydrogen, halogen, alkyl, etc.; R.sup.2 represents hydrogen, alkyl, acyl, etc.; G represents --CH.sub.2 --, --CH(OH)--, --CO--, etc.; Q represents alkylene; T represents --N(Rb)(Rc) (wherein Rb, Rc represents each alkyl etc.; or alternatively Rb and Rc are combined together to form cyclic amino); D represents --CH.sub.2 -- or --S--; A and B represent each carbonyl or thiocarbonyl, or are null; and m and n represent each 0, 1 to 4, provided that m+n represents an integer of 4 or less. This compound is useful as an antipsychotic drug having a reduced extrapyramidal side effect.

  一种缩合噻吩化合物，其通式为：##STR1## 或其药学上可接受的盐，其中环S代表噻吩环；R1代表氢、卤素、烷基等；R2代表氢、烷基、酰基等；G代表--CH2--、--CH(OH)--、--CO--等；Q代表亚烷基；T代表--N(Rb)(Rc)（其中Rb、Rc各自代表烷基等；或者Rb和Rc结合形成环状氨基）；D代表-- --或--S--；A和B各自代表羰基或硫羰基，或者为空；m和n各自代表0、1至4，条件是m+n代表4或以下的整数。该化合物作为具有减少锥体外系副作用的抗精神病药物是有用的。
• Substituted piperazine derivatives, the preparation thereofand their use as medicaments
  申请人：——

  公开号：US20030166637A1

  公开（公告）日：2003-09-04

  The present invention relates to substituted piperazine derivatives of general formula 1 , (I wherein R a , R b , R c , R f , R g , X, m and n are defined as in claim 1, the isomers and salts thereof, particularly the physiologically acceptable salts thereof, which are valuable inhibitors of the microsomal triglyceride-transfer protein (MTP), medicaments containing these compounds and their use, as well as the preparation thereof.

  本发明涉及一般式1的取代哌嗪衍生物（I），其中Ra、Rb、Rc、Rf、Rg、X、m和n的定义如权利要求书中所述，其异构体和盐，特别是其生理上可接受的盐，这些盐是微粒体甘油三酯转移蛋白（MTP）的有价值的抑制剂，含有这些化合物的药物以及它们的使用，以及其制备。
• Method for treating allergies using substituted pyrazoles
  申请人：——

  公开号：US20030069240A1

  公开（公告）日：2003-04-10

  A method for treating an allergic condition, including an atopic allergic condition, using substituted pyrazoles.

  使用取代吡唑烷类化合物治疗过敏症状的方法，包括特应性过敏症状。